PHARMACY

AstraZeneca granted preliminary injunction against Apotex

BY Alaric DeArment

WILMINGTON, Del. The U.S. District Court for the District of New Jersey has granted drug maker AstraZeneca a preliminary injunction to prevent a generic drug maker from launching a version of one of its asthma treatments.

The Anglo-Swedish drug maker announced Wednesday the injunction barring Apotex from launching a generic version of Pulmicort Respules (budesonide inhalation suspension) for the U.S. market.

The Food and Drug Administration granted approval for Apotex’s product on March 30, prompting AstraZeneca to file a patent litigation suit.

Patents covering Pulmicort Respules expire in 2018, with pediatric exclusivity lasting until the following year. Sales of Pulmicort products, including Pulmicort Respules, were $982 million in 2008.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Pfizer expands generics portfolio with Aurobindo, Claris deals

BY Alaric DeArment

NEW YORK A big pharmaceutical company has entered licensing agreements with two Indian generics companies, expanding its portfolio by 75 products.

Pfizer announced Wednesday that the agreements, with Aurobindo Pharma and Claris Lifesciences, would “significantly expand” the portfolio of medicines in its Established Products Business Unit, giving it products to market in North America, Europe, Australia, New Zealand and more than 70 emerging market countries.

“[Today’s] announcement demonstrates Pfizer’s commitment to improving the global public health landscape by making needed quality medicines – in a range of disease areas – accessible to underserved populations worldwide,” Pfizer chairman and CEO Jeff Kindler stated. “The off-patent marketplace worldwide too often suffers from quality and supply reliability issues.”

Under the terms of the agreements, Pfizer has acquired the rights to 55 pill drugs and five injected drugs from Aurobindo to sell in emerging markets, and 15 injected drugs from Claris to sell in developed markets.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Lilly, Medtronic to deliver diabetes education

BY Alaric DeArment

INDIANAPOLIS A drug maker and a medical device maker have announced a collaboration to provide education on care and management of diabetes.

Eli Lilly & Co. and Medtronic said their marketing and sales operations would work with healthcare professionals to deliver diabetes education for patients and caregivers affected by Type 1 diabetes, including the development of educational resources and classes around the initiation and intensive management of insulin, insulin pump therapy and continuous glucose monitoring.

“Medtronic and Lilly are joining together to help improve patient access to high-quality diabetes education,” Medtronic SVP and diabetes business unit president Chris O’Connell said. “Because diabetes management is complicated, it is crucial that physicians and patients have the best access to information and educational resources.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?